» Articles » PMID: 39104394

Synthesis, Characterization, and Mechanistic Insights into the Enhanced Anti-inflammatory Activity of Baicalin Butyl Ester Via the PI3K-AKT Pathway

Overview
Journal Front Pharmacol
Date 2024 Aug 6
PMID 39104394
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To investigate the anti-inflammatory activity and mechanism of Baicalin derivative (Baicalin butyl ester, BE).

Methods: BE was synthesized and identified using UV-Vis spectroscopy, FT-IR spectroscopy, mass spectrometry (MS) and high-performance liquid chromatography (HPLC) methods. Its anti-inflammatory potential was explored by an inflammation model. Network pharmacology was employed to predict the anti-inflammatory targets of BE, construct protein-protein interaction (PPI) networks, and analysis topological features and KEGG pathway enrichment. Additionally, molecular docking was conducted to evaluate the binding affinity between BE and its core targets. qRT-PCR analysis was conducted to validate the network pharmacology results. The organizational efficiency was further evaluated through octanol-water partition coefficient and transmembrane activity analysis.

Results: UV-Vis, FT-IR, MS, and HPLC analyses confirmed the successfully synthesis of BE with a high purity of 93.75%. anti-inflammatory research showed that BE could more effectively suppress the expression of NO, COX-2, IL-6, IL-1β, and iNOS. Network pharmacology and experiments validated that BE's anti-inflammatory effects was mediated through the suppression of SRC, HSP90AA1, PIK3CA, JAK2, AKT1, and NF-κB via PI3K-AKT pathway. Molecular docking results revealed that the binding affinities of BA to the core targets were lower than those of BE. The Log -value of BE (1.7) was markedly higher than that of BA (-0.5). Furthermore, BE accumulated in cells at a level approximately 200 times greater than BA.

Conclusion: BE exhibits stronger anti-inflammatory activity relative to BA, possibly attributed to its better lipid solubility and cellular penetration capabilities. The anti-inflammatory mechanism of BE may be mediated through the PI3K-AKT pathway.

References
1.
Wen Y, Wang Y, Zhao C, Zhao B, Wang J . The Pharmacological Efficacy of Baicalin in Inflammatory Diseases. Int J Mol Sci. 2023; 24(11). PMC: 10253382. DOI: 10.3390/ijms24119317. View

2.
Jiang P, Ye J, Jia M, Li X, Wei S, Li N . The common regulatory pathway of COVID-19 and multiple inflammatory diseases and the molecular mechanism of cepharanthine in the treatment of COVID-19. Front Pharmacol. 2022; 13:960267. PMC: 9354910. DOI: 10.3389/fphar.2022.960267. View

3.
Shi Y, Zhao X . Impact of the Plastein Reaction of Casein Hydrolysates in the Presence of Exogenous Amino Acids on Their Anti-Inflammatory Effect in the Lipopolysaccharide-Stimulated Macrophages. Foods. 2022; 11(2). PMC: 8775256. DOI: 10.3390/foods11020196. View

4.
Yan G, Chen L, Wang H, Wu S, Li S, Wang X . Baicalin inhibits LPS-induced inflammation in RAW264.7 cells through miR-181b/HMGB1/TRL4/NF-κB pathway. Am J Transl Res. 2021; 13(9):10127-10141. PMC: 8507057. View

5.
Kroliczewska B, Graczyk S, Kroliczewski J, Pliszczak-Krol A, Mista D, Zawadzki W . Investigation of the immune effects of on blood leukocytes and selected organs of the chicken's lymphatic system. J Anim Sci Biotechnol. 2017; 8:22. PMC: 5340046. DOI: 10.1186/s40104-017-0152-x. View